VANCOUVER, BC – February 5, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FRA: 1R3)
Izotropic Corporation is pleased to announce that a notice of allowance has been received from the United States Patent and Trademark office (“USPTO”) for the patent application No. 11/913494, entitled “Biopsy Systems For Breast Computed Tomography”.
The patent covers the use of Izotropic Corporation’s dedicated Breast CT Imaging System for robotic guided biopsy, giving physicians the ability to image and obtain samples of suspicious lesions and tumors for pathology testing.
This is an important development which will have a significant impact on our market entry strategy. Filing and prosecuting key patents is an integral part of commercializing breast CT and progress is being made to that end.
The UC Davis website describes one aspect of the ongoing clinic trials entitled “Breast CT Scanner for Earlier Cancer Detection” and the capabilities of breast CT technology: “The median size of breast cancer found using mammography is approximately 11 mm… we have found that breast CT may be able to routinely detect much smaller breast tumors, in the 3 to 5 mm range [which] would result in 1.5 year earlier detection over mammography.”
The Company believes that dramatic and meaningful advances in breast cancer detection will only occur when cancers can be identified and confirmed via biopsy at a much earlier stage. The combination of dedicated breast CT with robotic guided biopsy will be a disruptive combination that the Company believes will result in earlier detection and treatment of breast cancers.
ON BEHALF OF THE BOARD
Robert Thast, Chief Executive Officer
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.
The Company has the exclusive license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.
Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, fully funded $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.